Colorectal Cancer News
Colorectal Cancer Patients Not Affected By FDA's Avastin® Breast Cancer Decision
November 22, 2011
On November 18, the Food and Drug Administration (FDA) announced that it was revoking the agency’s accelerated approval of the metastatic breast cancer indication for Avastin® (bevacizumab).
This decision does not affect Avastin’s approved use for other types of cancers. Avastin® will continue to be a treatment option for those with advanced colon cancer. The Avastin® (bevacizumab) label includes the following approved indication:
Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment.
Patients should talk to their doctor if they have any questions.